Evidence map›Paper›PMID 29792191›Full record

ArticleHarm reduction journal2018

Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.

Jose Luis Burgos, Javier A Cepeda, James G Kahn, Maria Luisa Mittal, Emilio Meza, Raúl Rafael Palacios Lazos, Psyché Calderón Vargas, Peter Vickerman, Steffanie A Strathdee, Natasha K Martin

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Harm reduction journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Jose Luis BurgosDivision of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, USA.
Javier A CepedaDivision of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, USA. jacepeda@ucsd.edu.ORCID 0000-0003-0304-3172
James G KahnInstitute for Health Policy Studies, School of Medicine, University of California, San Francisco, USA.
Maria Luisa MittalDivision of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, USA.
Emilio MezaState Government of Oaxaca, Oaxaca, Mexico.
Raúl Rafael Palacios LazosCentro de Integracion Juvenil, Tijuana, Mexico.
Psyché Calderón VargasCentro de la Conducta, Tijuana, Mexico.
Peter VickermanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Steffanie A StrathdeeDivision of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, USA.
Natasha K MartinDivision of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, USA.
University of California San Diego · USUniversity of Bristol · GBInstituto Tecnológico de Oaxaca · MXUniversity of California, San Francisco · USUniversity of California System · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
University of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
University of California Global Health Institute Program for Fellows and ScholarsR25TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COHEN, CRAIG R, STRATHDEE, STEFFANIE A. · 2012 to 2017
$6.4M
Modeling Structural HIV Determinants in Substance Users and related populationsR01DA037773 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA, STRATHDEE, STEFFANIE A. · 2015 to 2017
$1.4M
MODELING THE IMPACT OF A POLICE EDUCATION PROGRAM ON HIV INCIDENCE AMONG PEOPLE WHO INJECT DRUGSK01DA043421 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CEPEDA, JAVIER · 2017 to 2021
$941k
FIC NIH HHS D43 TW009343FIC NIH HHS R25 TW009343FIC NIH HHS R25TW009343National Institute of Allergy and Infectious Diseases P30AI036214NIAID NIH HHS P30 AI036214NIDA NIH HHS K01 DA043421NIDA NIH HHS K01DA043421NIDA NIH HHS R01 DA015612NIDA NIH HHS R01 DA037773NIDA NIH HHS R01DA037773NIDA NIH HHS T32 DA023356NIDA NIH HHS T32DA023356
6 · The paper itself

Abstract

backgroundMexico recently enacted drug policy reform to decriminalize possession of small amounts of illicit drugs and mandated that police refer identified substance users to drug treatment. However, the economic implications of drug treatment expansion are uncertain. We estimated the costs of opioid substitution therapy (OST) provision in Tijuana, Mexico, where opioid use and HIV are major public health concerns.

methodsWe adopted an economic health care provider perspective and applied an ingredients-based micro-costing approach to quantify the average monthly cost of OST (methadone maintenance) provision at two providers (one private and one public) in Tijuana, Mexico. Costs were divided by type of input (capital, recurrent personnel and non-personnel). We defined "delivery cost" as all costs except for the methadone and compared total cost by type of methadone (powdered form or capsule). Cost data were obtained from interviews with senior staff and review of expenditure reports. Service provision data were obtained from activity logs and senior staff interviews. Outcomes were cost per OST contact and cost per person month of OST. We additionally collected information on patient charges for OST provision from published rates.

resultsThe total cost per OST contact at the private and public sites was $3.12 and $5.90, respectively, corresponding to $95 and $179 per person month of OST. The costs of methadone delivery per OST contact were similar at both sites ($2.78 private and $3.46 public). However, cost of the methadone itself varied substantially ($0.34 per 80 mg dose [powder] at the private site and $2.44 per dose [capsule] at the public site). Patients were charged $1.93-$2.66 per methadone dose.

conclusionsThe cost of OST provision in Mexico is consistent with other upper-middle income settings. However, evidenced-based (OST) drug treatment facilities in Mexico are still unaffordable to most people who inject drugs.

Indexed as

Analgesics, OpioidCosts and Cost AnalysisDelivery of Health CareDirectly Observed TherapyFees and ChargesHarm ReductionHumansMethadoneMexicoOpiate Substitution TreatmentOpioid-Related DisordersPrivate SectorPublic SectorSubstance Abuse Treatment CentersAnalgesics, OpioidMethadoneCostMethadoneMexicoOpioid substitution therapy

Identifiers

PMID29792191
PMCPMC5967039
OpenAlexW2806420310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.